<DOC>
	<DOC>NCT00724958</DOC>
	<brief_summary>The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.</brief_summary>
	<brief_title>Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)</brief_title>
	<detailed_description>This study population was chosen from a non-probability sample</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects with active luminal and/or fistulizing CD. Per summary of product characteristics.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>